Refractory Chronic Hand Eczema Responds to Oral Upadacitinib
Keywords:
Hand dermatitis, Hand Eczema, Upadacitinib, Janus kinase inhibitor.References
Agarwal US, Besarwal RK, Gupta R, Agarwal P, Napalia S. Hand eczema. Indian J Dermatol. 2014;59(3):213-224. DOI:10.4103/0019-5154.131372. PMID: 24891648. PMCID: PMC4037938.
Thyssen JP, Schuttelaar MLA, Alfonso JH, et al. Guidelines for diagnosis, prevention, and treatment of hand eczema. Contact Dermatitis. 2022;86(5):357-378. DOI:10.1111/cod.14035. PMID: 34971008.
Elsner P, Agner T. Hand eczema: treatment. J Eur Acad Dermatol Venereol. 2020;34 Suppl 1:13-21. DOI:10.1111/jdv.16062.
Guttman-Yassky E, Teixeira HD, Simpson EL, et al. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials [published correction appears in Lancet. 2021 Jun 5;397(10290):2150]. Lancet. 2021;397(10290):2151-2168. DOI: 10.1016/S0140-6736(21)00588-2.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Nada Alghamdi, Abdullah AN.Aljalfan, Abdulmajeed S. Alharbi, Omar I.Alrubaish, Serene R.Almuhaidib

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Dermatology Practical & Conceptual applies a Creative Commons Attribution License (CCAL) to all works we publish (http://creativecommons.org/licenses/by-nc/4.0/). Authors retain the copyright for their published work.